Fri, Sep 19, 2014, 8:19 AM EDT - U.S. Markets open in 1 hr 11 mins


% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • posting_clown posting_clown Dec 2, 2013 5:10 PM Flag

    Has Geron ever said how much it costs per dose?

    I've read a few times that Imetelstat is difficult and expensive to make but I've never heard it quantified

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • No actual number but implied in the small amounts needed for trials expensive. A benefit of shutting down the Lung and Breast trials is they probably had plenty on hand for those trials that could now be shifted at no additional cost to the Myelofibrosis trial. I'll assume beneit of larger scale production would be lowered price.

      I had an exchange a while back with Sergei Gryaznov, the chemist who created the lipidated version of GRN163. There had been mention of acid stability of the compound and I asked him about the possibility of making an oral version of it. Obvious huge advantage if possible. He indicated a small pilot study was under way in animals but now he is no longer at Geron it would be interesting to know the results.

    • Imetelstat is a lipid-conjugated 13-mer oligonucleotide sequence.

      Go to IDT-DNA to estimate the RNA oligo synthesis cost (for a ballpark idea) and then you have to consider the cost of conjugating the lipid to it.

      I cannot imagine this being a problem in terms of technology and cost.

      Sentiment: Strong Buy

    • It is to early for Geron to publicize what a dosage regimen will cost. They have not even publicized or maybe even determined what a typical dosage regimen will be. However, the cost of treating a patient should be way less than Dendreon's Provenge. Where as Provenge requires the ex vivo treatment of a patients immune cells to be injected back into the patient Imetelstat is a single step IV injection. No customized preparation for each patient is required.

      Sentiment: Hold

2.31-0.03(-1.28%)Sep 18 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.